SCHEMBL6804633

SCHEMBL6804633

CC(=CC(C(C)C)N(C)C(=O)[C@@H](N)C(C)(C)C)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 6/20 0.47
TUBB1 Q9H4B7 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16056549 1.00 DPP4 (0.47) DPP4TUBB1
SCHEMBL4368812 1.00 DPP4 (0.47) DPP4TUBB1
SCHEMBL13682708 1.00 DPP4 (0.47) DPP4TUBB1
SCHEMBL4368810 1.00 DPP4 (0.47) DPP4TUBB1
SCHEMBL6804629 1.00 DPP4 (0.47) DPP4TUBB1
Hydrochloric Acid SCHEMBL6673070 0.98 DPP4 (0.46) DPP4TUBB1
Hydrochloric Acid SCHEMBL4368798 0.98 DPP4 (0.46) DPP4TUBB1
Hydrochloric Acid SCHEMBL22283977 0.98 DPP4 (0.46) DPP4TUBB1
Hydrochloric Acid SCHEMBL6673067 0.98 DPP4 (0.46) DPP4TUBB1
Hydrochloric Acid SCHEMBL4368791 0.98 DPP4 (0.46) DPP4TUBB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230390354-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2023-12-07 US disclosed
US-20230265173-A1 SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES ZYMEWORKS BC INC. (CA) 2023-08-24 US disclosed
US-11617777-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same ZYMEWORKS BC INC. 2023-04-04 US disclosed
US-11560422-B2 Sulfonamide-containing linkage systems for drug conjugates ZYMEWORKS INC. 2023-01-24 US disclosed
EP-3086815-B1 SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES ZYMEWORKS INC (CA) 2022-02-09 EP disclosed
EP-3087091-B1 VAR2CSA-DRUG CONJUGATES ZYMEWORKS INC (CA) 2021-10-20 EP disclosed
US-10675355-B2 VAR2CSA-drug conjugates VAR2 PHARMACEUTICALS APS (DK) 2020-06-09 US disclosed
US-20190269785-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2019-09-05 US disclosed
EP-2968440-B1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS INC (CA) 2019-06-05 EP disclosed
US-10201614-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same ZYMEWORKS INC. 2019-02-12 US disclosed
US-20170246310-A1 VAR2CSA-DRUG CONJUGATES ZYMEWORKS INC. (CA) 2017-08-31 US disclosed
US-20170029490-A1 SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES ZYMEWORKS INC. (CA) 2017-02-02 US disclosed
US-9522876-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same ZYMEWORKS INC. 2016-12-20 US disclosed
EP-3086815-A1 SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES Zymeworks Inc. (CA) 2016-11-02 EP disclosed
EP-3087091-A1 VAR2CSA-DRUG CONJUGATES Zymeworks Inc. (CA) 2016-11-02 EP disclosed
US-20160038606-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2016-02-11 US disclosed
WO-2015095953-A1 SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) 2015-07-02 WO disclosed
WO-2015095952-A1 VAR2CSA-DRUG CONJUGATES THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) 2015-07-02 WO disclosed
US-20140315954-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2014-10-23 US disclosed
US-20040121965-A1 Method of treating resistant tumors WYETH HOLDINGS CORPORATION (US) 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265173-A1 SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES MPST, TPST2, SULT1A1 DPP4 1387/4885TUBB1 516/4885
US-20170246310-A1 VAR2CSA-DRUG CONJUGATES VARS1, GUSB, VAV1 DPP4 1316/4885TUBB1 216/4885
US-11617777-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same CCNB1, PLK1, BOD1L1 DPP4 2986/4885TUBB1 106/4885
US-20140315954-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, CCNB2, CCNB3 DPP4 2225/4885TUBB1 236/4885
US-10675355-B2 VAR2CSA-drug conjugates VARS1, GUSB, VAV1 DPP4 1316/4885TUBB1 216/4885
US-10201614-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same CCNB1, PLK1, CCNB2 DPP4 2974/4885TUBB1 107/4885
US-20190269785-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, PLK1, BOD1L1 DPP4 2986/4885TUBB1 106/4885
US-20230390354-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, PLK1, BOD1L1 DPP4 2986/4885TUBB1 106/4885
US-11560422-B2 Sulfonamide-containing linkage systems for drug conjugates MPST, TPST2, SULT1A1 DPP4 1387/4885TUBB1 516/4885
US-20040121965-A1 Method of treating resistant tumors SLC11A2, VHL, REN DPP4 4160/4885TUBB1 199/4885
US-20160038606-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, PLK1, CCNB2 DPP4 2974/4885TUBB1 107/4885
US-20170029490-A1 SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES MPST, TPST2, SULT1A1 DPP4 1387/4885TUBB1 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.